Intermolecular interactions in the crystal structures of potential HIV-1 integrase inhibitors

被引：20

作者：

Majerz-Maniecka, K

Musiol, R

Nitek, W

Oleksyn, BJ

Mouscadet, JF

Le Bret, M

Polanski, J

机构：

[1] Jagiellonian Univ, Fac Chem, PL-30060 Krakow, Poland

[2] Silesian Univ, Inst Chem, CNRS, UMR 8532, PL-40007 Katowice, Poland

[3] Ecole Normale Super, LBPA, F-94235 Cachan, France

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2006年 / 16卷 / 04期

关键词：

crystal structure; HIV-1 integrase inhibitor; quinoline;

D O I：

10.1016/j.bmcl.2005.10.083

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

2-[(2.5-dichloro-4-nitro-phenylamino)-methoxy-methyl]-8-hydroxy-quinoline 1 and 2-methyl-quinoline-5,8-dione-5-oxime 2 were obtained as potential HIV-1 integrase inhibitors and analyzed by X-ray crystallography. Semiempirical theoretical calculations of energy preferred conformations were also carried out. The crystal structures of both compounds are stabilized via hydrogen bonds and pi-pi stacking interactions. The planarity of compound 1 is caused by intramolecular hydrogen bonds. (c) 2005 Elsevier Ltd. All rights reserved.

引用

收藏

页码：1005 / 1009

页数：5

相关论文

共 21 条

[1] SIR92 - a program for automatic solution of crystal structures by direct methods [J].

ALTOMARE, A ;

CASCARANO, G ;

GIACOVAZZO, G ;

GUAGLIARDI, A ;

BURLA, MC ;

POLIDORI, G ;

CAMALLI, M .

JOURNAL OF APPLIED CRYSTALLOGRAPHY, 1994, 27 :435-435

[2]

Burgi H.-B., 1994, STRUCTURE CORRELATIO

[3] THE DEVELOPMENT AND USE OF QUANTUM-MECHANICAL MOLECULAR-MODELS .76. AM1 - A NEW GENERAL-PURPOSE QUANTUM-MECHANICAL MOLECULAR-MODEL [J].

DEWAR, MJS ;

ZOEBISCH, EG ;

HEALY, EF ;

STEWART, JJP .

JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1985, 107 (13) :3902-3909

[4] Fragment-based drug discovery [J].

Erlanson, DA ;

McDowell, RS ;

O'Brien, T .

JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (14) :3463-3482

[5] ORTEP-3 for Windows - a version of ORTEP-III with a Graphical User Interface (GUI) [J].

Journal of Applied Crystallography, 1997, 30 (pt 5)

[6] Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: A platform for antiviral drug design [J].

Goldgur, Y ;

Craigie, R ;

Cohen, GH ;

Fujiwara, T ;

Yoshinaga, T ;

Fujishita, T ;

Sugimoto, H ;

Endo, T ;

Murai, H ;

Davies, DR .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (23) :13040-13043

[7] Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells [J].

Hazuda, DJ ;

Felock, P ;

Witmer, M ;

Wolfe, A ;

Stillmock, K ;

Grobler, JA ;

Espeseth, A ;

Gabryelski, L ;

Schleif, W ;

Blau, C ;

Miller, MD .

SCIENCE, 2000, 287 (5453) :646-650

[8] Rational design and synthesis of novel dimeric diketoacid-containing inhibitors of HIV-1 integrase: Implication for binding to two metal ions on the active site of integrase [J].

Long, YQ ;

Jiang, XH ;

Dayam, R ;

Sanchez, T ;

Shoemaker, R ;

Sei, S ;

Neamati, N .

JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (10) :2561-2573

[9] Styrylquinoline derivatives:: A new class of potent HIV-1 integrase inhibitors that block HIV-1 replication in CEM cells [J].

Mekouar, K ;

Mouscadet, JF ;

Desmaële, D ;

Subra, F ;

Leh, H ;

Savouré, D ;

Auclair, C ;

d'Angelo, J .

JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (15) :2846-2857

[10]

Mitchell T., 2005, INNOVATIONS PHARM TE, V16, P34